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Background: Among men and women diagnosed with colorectal cancer (CRC), 20–50%
will develop a cancer recurrence. Cancer recurrences are not routinely captured by most
population-based registries; however, linkage across Danish registries allows for the devel-
opment of predictive models to detect recurrence. Successful application of such models in
population-based settings requires validation against a gold standard to ensure the accuracy
of recurrence identification.
Objective: We apply a recently developed validation study design for prospectively col-
lected validation data to validate predicted CRC recurrences against gold standard diagnoses
from medical records in an actively followed cohort of CRC patients in Denmark.
Methods: We use a Bayesian monitoring framework, traditionally used in clinical trials, to
iteratively update classification parameters (positive and negative predictive values, and
sensitivity and specificity) in an adaptive validation substudy design. This design allows
determination of the sample size necessary to estimate the corresponding parameters and to
identify when validation efforts can cease based on predefined criteria for parameter values
and levels of precision.
Results: Among 355 men and women diagnosed with CRC in Denmark and actively
followed semi-annually, there were 63 recurrences diagnosed by active follow-up and 70
recurrences identified by a predictive algorithm. The adaptive validation design met stopping
criteria for the classification parameters after 120 patients had their recurrence information
validated. This stopping point yielded parameter estimates for the classification parameters
similar to those obtained when the entire cohort was validated, with 66% less patients needed
for the validation study.
Conclusion: In this proof of concept application of the adaptive validation study design for
outcome misclassification, we demonstrated the ability of the method to accurately determine
when sufficient validation data have been collected. This method serves as a novel validation
substudy design for prospectively collected data with simultaneous implementation of
a validation study.
Keywords: validation study design, colorectal cancer recurrence
Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the
third leading cause of cancer-related mortality among men and women globally.1
Improvements in diagnostic workup, including screening and in surgical techniques
and medical treatments, have contributed to an increase in the survival rates for
CRC patients.2,3 Current survival estimates are largely dependent on the stage at
diagnosis, with estimated 5-year survival proportions of 90%, 70%, and 10% for
stage I–II, stage III, and metastatic disease, respectively.4
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A cancer recurrence is broadly defined as a return of
the original cancer following an initial disease-free
period.5,6 A cancer recurrence can happen locally (at or
near the original site), regionally (in surrounding lymph
nodes), or distally (at a distant anatomical site).7 Among
individuals diagnosed with CRC, the 5-year risk of recur-
rence is between 20% and 50%, depending on stage and
other tumor characteristics at diagnosis.7–11 Treatments
for local or regional (stage I–III) disease include surgery
alone or combinations of surgery, chemotherapy, and
radiation therapy, with the intent of curing the patient
of their disease.12 Following curative treatment and an
apparent disease-free period, a recurrence is a necessary
preceding condition before CRC-specific mortality.
However, due to the lack of population-wide surveillance
data on the rate of recurrence, CRC-specific mortality is
the most often used outcome to measure population-wide
progress in CRC treatment. The use of mortality as the
primary surveillance endpoint may be suboptimal, as
recurrent tumors are amenable to therapy, so not all
patients who have a recurrence will die from it.
Furthermore, focusing on mortality impedes the identifi-
cation of factors related directly to recurrence. We have,
for example, shown a different relation between use of
statins and colorectal cancer recurrence versus colorectal
cancer-specific mortality in the same cohort of early-stage
colorectal cancer patients, suggesting that the two out-
comes can yield different epidemiologic estimates of
association.13 Direct study of recurrence is therefore
often the preferable approach for clinical epidemiology
studies of CRC outcomes.
Unfortunately, recurrence data are not routinely col-
lected by most population-based registries, including the
Danish registries. The Danish registry system does allow
unambiguous linkage across registries,14 and these lin-
kages facilitated the development of an algorithm to
predict CRC recurrences using diagnostic and procedure
codes across multiple registries.15 Development and use
of such algorithms in epidemiologic research requires
a validation substudy to compare quantitatively algo-
rithm-defined recurrences with gold standard—clinically
recorded—diagnoses. Validation substudies measure the
accuracy of the algorithm’s classification of recurrences,
and the validation parameters they produce can be used
in quantitative bias analyses to bias-adjust the influence
of measurement error on association estimates. However,
methods for validation substudy design using prospec-
tively collected data have not been fully developed.
Historically, validation study design has received far
less methodologic development than standard study
designs, such as case-control or cohort studies. What
limited research exists on validation studies often pertains
to selecting sample sizes. Further, most previous gui-
dance on designing validation substudies pertained to
scenarios in which study enrolment and follow-up had
been completed before the validation study has been
implemented.16–18 In this proof of concept study, we
apply a recently developed validation study design for
prospectively collected validation data to validate CRC
recurrences identified through an algorithm against gold
standard diagnoses from medical records in an actively
followed cohort of CRC patients in Denmark. We use the
adaptive validation design to model when sufficient vali-
dation data would have been collected to meet
a predefined stopping rule and estimate the classification
parameters.
Materials and Methods
Study Population
We included Danish CRC patients who underwent sur-
gery and were registered with the Danish Colorectal
Cancer Group (DCCG) database.19 All patients had
been enrolled at Aalborg Hospital into an observation
cohort or into a randomized trial. The observation cohort
consisted of consenting patients admitted between
October 2003 and November 2005 for intended curative
surgery.20 The COLOFOL randomized trial (clinicaltrials.
gov identifier NCT00225641) enrolled in stage II and III
patients from January 2006 to January 2011 and com-
pared two follow-up regimens after surgical resection.21
Both cohorts received active biennial follow-up for color-
ectal cancer recurrence after completion of primary ther-
apy, and this follow-up information was treated as the
gold standard.
Analytic Variables
Recurrences: We defined CRC recurrences as tumor
growth at or near the site of the original tumor and in
the same organ, or metastases to tissue adjacent to the
original tumor site, or metastases to a distant organ. The
CRC recurrence prediction algorithm used four indepen-
dent data sources.15 Briefly, recurrences based on the
algorithm were defined as the presence of at least one of
the following:
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1. Danish National Patient Registry (DNPR)-
registered or Danish Cancer Registry (DCR)-
registered metastasis codes (ICD10 DC76–DC80),
180 days or more after first colorectal cancer
surgery.22,23
2. DNPR-registered cytostatic therapy codes, 180 days
or more after first colorectal cancer surgery.
3. Danish Pathology Registry SNOMED code combi-
nations recorded 180 days or more after first color-
ectal cancer surgery, and without a new primary
cancer diagnosis registered in DNPR or DCR.24
4. A code specific for local or regional colorectal
cancer recurrence in the DNPR any time after pri-
mary diagnosis.
This algorithm was previously applied to a cohort of all
Danish colorectal cancer patients to understand the popu-
lation-wide descriptive epidemiology of colorectal cancer
recurrence.7
Statistical Analysis
We used the actively followed CRC cohort’s recurrence
diagnoses as the gold standard and performed two sets of
validation studies to estimate positive and negative pre-
dictive values (PPVand NPV, respectively), and sensitivity
and specificity classification parameters. Conditioning on
the algorithm’s classification of recurrence status allowed
calculation of the PPV and NPV. Conversely, conditioning
on gold standard recurrence status allowed calculation of
the sensitivity and specificity of recurrence classification.
For each of the two validation sets, we used the framework
of Bayesian monitoring methods to identify when
a sufficient sample size had been obtained to meet
a prespecified threshold value and level of precision for
these four classification parameters.25 Bayesian monitor-
ing techniques have been used in clinical trials to estimate
treatment efficacy while trial data accumulate, and to
optimize randomization allocation schemes as data accrue.
We extended this framework to prospectively collected
validation data to optimize use of study resources when
estimating classification parameters. Our main goal in this
analysis was to model when sufficient validation data
would have been collected to establish the validity of the
algorithm, or, conversely, to determine whether to view the
algorithm as untenable for use in classifying CRC recur-
rence. Although the data from the actively followed CRC
cohort were already complete, we simulated the two vali-
dation scenarios as if the data were being collected
prospectively. To estimate the PPV and NPV, validation
study members were ordered chronologically by the date
of their algorithm-ascertained CRC recurrence. Similarly,
to estimate the sensitivity and specificity, validation study
members were ordered chronologically by the date of their
CRC recurrence recorded from active follow-up. This
ordering allowed for the selection of participants and cal-
culation of classification parameters as if validation data
were accruing simultaneously with other cohort data over
follow-up.
Once cohort members were chronologically ordered,
we used an iterative beta-binomial Bayesian model,
which updates the PPV/NPV or sensitivity/specificity,
which we designate θ, over regular follow-up intervals.
Each classification parameter is a proportion, so can be
modelled with a beta prior distribution and binomial like-
lihood. We began by assigning a noninformative beta prior
for each parameter, Prior θ ~Beta α ¼ 1; β ¼ 1ð Þ, where
θ is the validation parameter of interest. We update this
distribution iteratively with the likelihood contributed by
new validation data (yj) to calculate a new posterior dis-
tribution for each parameter for each sample:
Time 1 : p θjy1ð Þ / p y1jθð Þp θð Þ
Time 2 : p θjy2; y1ð Þ / p y2jθð Þpðθjy1Þ
Time j : p θjyj; . . . y2; y1
 
/ p yjjθ
 
pðθjyj1; . . . y2; y1Þ
Each time interval represents the updated classification
parameter after new validation data have been added to
the prior validation data collected, and this iterative pro-
cess can be continued until stopping criteria have been met
or until data collection is complete. To establish intervals
after which to update estimates, we evaluated the design
under two scenarios. First, once five algorithm-ascertained
recurrences had accumulated over the follow-up period,
we selected those five individuals and also, at random and
without replacement, we sampled five individuals without
algorithm-ascertained recurrences from the set of cohort
participants without an algorithm-ascertained recurrence
by that point in the study’s follow-up (i.e., a 10-person
validation set at each time interval). These were used to
estimate the PPVs and NPVs, updating the estimate from
the preceding time interval. This updating was done itera-
tively over the complete study period. We used identifica-
tion of five recurrences to trigger the computation because
Dovepress Collin et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
DovePress
115
 
C
lin
ic
al
 E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.5
7.
10
1.
74
 o
n 
14
-M
ar
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
recurrences were (and were expected to be) much less
common than lack of recurrence, so the latter were always
relatively abundant. Second, we repeated the analysis
using 10 recurrences instead of five to trigger the compu-
tation (ie, a 20-person validation set at each time interval).
Use of five or ten recurrences to trigger computation was
meant to simulate the accrual of sufficient sample (10 or
20) to justify sending a medical record abstractor to a site
to complete the validation. In the second validation set, we
repeated these two scenarios using the recurrences
recorded from the actively followed cohort, which allowed
for estimation of sensitivity and specificity.
In each validation substudy, we assumed that sufficient
validation data had been collected once the classification
parameters met 1) a predefined threshold and 2)
a corresponding level of precision. When estimating the
PPV and NPV, we assumed that the validation sample was
sufficiently large if the lower credible bound (2.5th percen-
tile) of both the PPV and NPV exceeded 0.80. We likewise
assumed that validation was futile if the upper credible
bound (97.5th percentile) was less than 0.80. The choice of
0.80 as the threshold was informed by the content.
Assuming that the algorithm would be considered valid
if the point estimate for PPV and NPV were near 0.90,
then the lower bound for the CI would need to reach at
least 0.80. For the precision criterion for PPVand NPV, we
assumed that validation efforts would cease if the credible
interval width—defined as the absolute difference between
the upper and lower CI—was less than 0.15. In our esti-
mation of sensitivity and specificity, we used results from
the Danish population-wide cohort study to inform an
allowable false-positive rate.7 In this population-based
study, the observed 5-year risk of recurrence, using recur-
rences identified from the algorithm, was approximately
25%. If we assumed that the true risk of recurrence has
a lower bound of 20% (informed by content), this limits
the false-positive rate to 0.10, leading to the cut-off of
≥0.90 for the 2.5th percentile of the lower credible bound
for both the sensitivity and specificity classification para-
meters as an indicator that validation had been optimized.
For the precision criterion, we assumed that validation
efforts could cease if the credible interval width was less
than 0.08.
Results
The combined CRC cohort and clinical trial cohorts used
for this analysis included 355 CRC patients, of whom 63
(18%) had a recurrence detected by gold-standard active
follow-up. According to the predictive algorithm we are
validating, there were 70 (20%) recurrences over the
course of follow-up. In the complete validation data,15
the PPV and NPV at the end of the study period were
0.86 (95% CI 0.75, 0.93) and 0.99 (95% CI 0.97, 1.00),
respectively (Table 1). The sensitivity and specificity of
classification of recurrence at the end of follow-up were
0.95 (95% CI 0.87, 0.99) and 0.97 (95% CI 0.94, 0.98),
respectively (Table 1).
PPV and NPV Classification Parameters
When recurrences were identified by the algorithm, the
adaptive validation design identified when sufficient infor-
mation had been collected to cease validation efforts
(Table 1 and Figure 1). When 10 individuals were included
in the validation set at each time interval, the adaptive
validation approach reached the stopping rule for threshold
and for precision after validation data from 110 individuals
had been collected. The final estimated PPV and NPV
classification parameters were 0.89 (95% CI 0.80, 0.95)
and 0.96 (95% CI 0.90, 0.99) respectively, which are good
approximations to the values obtained from the complete
data (Table 1). When 20 individuals were included in the
validation at each time interval, the adaptive validation
approach identified that the stopping criteria had been
reached after validation information from 120 persons
had been collected. The final estimated PPV and NPV
classification parameters were 0.90 (95% CI 0.82, 0.96)
and 0.98 (95% CI 0.94, 1.00), respectively, which are
again good approximations to the values obtained from
the complete data (Table 1). In general, estimates were
Table 1 Estimates of PPV, NPV, Sensitivity and Specificity
Classification Parameters for Possible Outcome Misclassification
of CRC Recurrence from the Adaptive Validation Substudy Design
Method PPV NPV Number
Validated
Complete data 0.86 (0.75, 0.93) 0.99 (0.97, 1.00) 355
Adaptive
Validation –10
0.89 (0.80, 0.95) 0.96 (0.90, 0.99) 110
Adaptive
Validation –20
0.90 (0.82, 0.96) 0.98 (0.94, 1.00) 120
Sensitivity Specificity
Complete data 0.95 (0.87, 0.99) 0.97 (0.94, 0.98) 355
Adaptive
Validation –10
0.96 (0.88, 0.99) 0.95 (0.89, 0.99) 120
Adaptive
Validation –20
0.95 (0.891, 0.99) 0.98 (0.94, 1.00) 120
Collin et al Dovepress
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more precise when 20 individuals were sampled at each
update step.
Sensitivity and Specificity Classification
Parameters
Similar to the PPV and NPV validation, the adaptive valida-
tion method identified when sufficient validation efforts had
been expended, although this did not reach the desired stop-
ping criteria when 10 individuals were included in the valida-
tion set at each time interval. When 10 individuals were
included in the validation set at each time interval, the esti-
mates of sensitivity and specificity were closest to the criteria
for stopping once 120 individuals had their recurrence infor-
mation validated. The sensitivity and specificity estimates
were 0.95 (95% CI 0.89, 0.99) and 0.95 (95% CI 0.89,
0.99), respectively (Figure 2), which are good approximations
to the values obtained from the complete data. When 20
individuals were included in the validation set at each time
interval, the estimates of sensitivity and specificity met the
criteria for stopping once 120 individuals were included, with
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Figure 1 Adaptive validation using (A) 10-person and (B) 20-person validation at a time among CRC recurrences identified through the algorithm to estimate the positive
and negative predictive values.
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improved precision over the 10-person validation approach.
The sensitivity and specificity estimates were 0.95 (95% CI
0.89, 1.00) and 0.98 (95% CI 0.94, 1.00), respectively
(Figure 2), which are again good approximations to the values
obtained from the complete data.
Discussion
In this proof of concept validation study, we illustrate that the
adaptive validation approach readily optimized the estimates
of classification parameters for the ascertainment of CRC
recurrences by a predictive algorithm. This evaluation was
carried out for the PPV, NPV, sensitivity, and specificity—all
of which showed that validation information from only ~120
individuals was needed to meet the predefined threshold and
precision criteria of the estimates of the parameters of inter-
est. As the original development of the algorithm used the
actively followed cohort (n=355) as a validation substudy,
we knew the overall classification parameters, allowing
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Figure 2 Adaptive validation using (A) 10-person and (B) 20-person validation at a time among CRC recurrences identified in the actively followed cohort to estimate the
sensitivity and specificity.
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comparison of the parameters estimated using the adaptive
design to the underlying parameters when the entire cohort’s
complete data had been validated. These results suggest that
235 of the 355 cohort members (66%) added only marginal
value to the validation study results.Were these 235 validated
by a resource-intensive strategy, such as medical record
review, use of an adaptive validation design would have
saved considerable research resources.
As interest expands in cancer recurrences as an endpoint
for cancer survivorship studies, population-based registries
without standardized collection of recurrence information
may apply similar algorithms with multiple data streams to
identify recurrences.26,27 Such an undertaking requires
extensive and often expensive validation, and monitoring
of the validation results as well the expenses allocated to
them. Previous methods to design validation studies, such
as the simple random sample or balanced design, require
completed data collection before implementation.17 The
adaptive validation design allows thoughtful consideration
of which validation data will be most informative for the
study as follow-up data accrue. Through iterative updating
of estimates of bias parameters, researchers can ensure
a purposeful design of internal validation substudies, stop-
ping validation data collection when additional information
will add only marginal value or when additional informa-
tion is likely to be futile. This approach may save research-
ers valuable resources that can be redirected to additional
data collection without sacrificing the quality of the valida-
tion data collected. For prospectively collected data, this
design allows the simultaneous implementation of the vali-
dation with the collection of the cohort’s data instead of the
traditional study designs that require waiting until all data
have been collected before beginning validation.
This study is not without limitations. We used data that
had already been collected and validated, then simulated the
validation studies as if they were happening in real time, so
estimates of the classification parameters from the complete
data were known. The advantage was that use of a complete
validation study allowed a comparison of estimates
obtained when the stopping rule was met with estimates in
the complete data. However, our choice of stopping point
was inevitably informed by knowledge of the results from
the complete data, which would not be available when
undertaking a truly prospective design. In that case, the
stopping rule would have to be informed by another strategy
or by content-specific knowledge, possibly from similar
validation studies in external populations or desired end-
points. Additionally, validation data were only available
from two actively followed patient populations at one hos-
pital site in Denmark, which may have led to bias in the
classification parameters if there are regional differences in
clinical practice. Furthermore, we did not base our stopping
rule on an estimate of an exposure-outcome association of
interest, which would have changed our sampling strategy
by requiring sampling and estimation of at least the predic-
tive values within categories of the exposure. An interesting
finding was that the majority of the misclassified indivi-
duals occurred in the last time period of the study’s follow-
up, which may suggest that the actively followed cohort lost
patients to follow-up before a recurrence could be docu-
mented, and that the accuracy of the algorithm was better
than previously reported (Supplemental Figures 1 and 2).13
The previous validation compared the cumulation of recur-
rences in the actively followed cohort using the complete
data at the end without insight into the trend in classification
over time. Our results indicate that the trend over time may
be an important consideration, which was only apparent
when we evaluated the time-dependence of the estimates
of the classification parameters.
Conclusions
In this proof of concept application of the adaptive valida-
tion study design for outcome misclassification, we
demonstrated the ability of the method to accurately deter-
mine when sufficient validation data have been collected.
This method serves as a novel validation substudy design
for prospectively collected data with simultaneous imple-
mentation of a validation study.
Abbreviations
CRC, colorectal cancer; PPV, positive predictive value;
NPV, negative predictive value; DCR, Danish Cancer
Registry; DNPR, Danish National Patient Registry.
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